Home›Trial›NCT07154238
NCT07154238ENROLLING BY INVITATION

Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.

Study Summary

The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.

Conditions
Obesity
Interventions / Drugs
No treatment given
View on ClinicalTrials.gov ↗
Sponsor
NVO
Novo Nordisk
Diabetes/Obesity
F12/100
Study Details
Enrollment2546 participants
Primary Completion—
Lead SponsorNovo Nordisk A/S
Data Retrieved2026-04-11 02:55:47.366540+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 2,546 participants
Sponsor Catalyst Profile

Novo Nordisk (NVO) is the sponsoring company for this trial. BiotechSign currently grades this company F (12/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NVO Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.